Exabis Library
Welcome to the e-CCO Library!
DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP55: The increasing burden of direct and indirect costs of IBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP56: Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP56: Long-term disease progression and resective surgery rates in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP57: Development and validation of a convolutional neural network for the automatic detection of enteric ulcers and erosions in capsule endoscopy: A multicentric study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP57: Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP58: An artificial intelligence–driven scoring system to measure histological disease activity in Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM